Clinical Edge Journal Scan

Airflow limitation tied to increased risk for lung cancer


 

Key clinical point : Airflow limitation is linked to an increased risk for lung cancer, with the association being pronounced in ever smokers.

Major finding : Airflow limitation vs no limitation was associated with a higher risk for lung cancer (adjusted hazard ratio [aHR] 1.7; 95% CI 1.4-2.3). The association was greater among current smokers (HR 2.2; 95% CI 1.5-3.2) and former smokers (HR 2.1; 95% CI 1.4-3.2) compared with never smokers (HR 0.9; 95% CI 0.4-2.1).

Study details : The data come from a prospective population-based cohort study involving 98,630 participants.

Disclosures: No funding information was available. HJM Groen, R Vliegenthart, and W Timens declared receiving personal fees from pharmaceutical companies outside this work. The other authors reported no disclosures.

Source: Du Y et al. Airflow limitation increases lung cancer risk in smokers: The Lifelines Cohort Study. Cancer Epidemiol Biomarkers Prev. 2022;31(7):1442–1449 (May 9). Doi: 10.1158/1055-9965.EPI-21-1365

Recommended Reading

The shifting sands of lung cancer screening
MDedge Hematology and Oncology
Lung cancer treatment combo may be effective after ICI failure
MDedge Hematology and Oncology
Early-stage NSCLC: EGFR mutation predicts longer survival
MDedge Hematology and Oncology
NSCLC: Cell-free RNA beneficial for early detection and prognosi
MDedge Hematology and Oncology
Stage III NSCLC: Preoperative FDG PET/CT tied to longer survival
MDedge Hematology and Oncology
Additional postoperative radiotherapy prolongs survival in stage I-IIA SCLC
MDedge Hematology and Oncology
NSCLC: Meta-analysis cautions concomitant use of gastric acid suppressants and immunotherapy
MDedge Hematology and Oncology
NSCLC: rhG-CSF tied to increased metastasis risk following postoperative chemotherapy
MDedge Hematology and Oncology
Concurrent ADT for prostate cancer improves survival in subsequently diagnosed lung cancer
MDedge Hematology and Oncology
Network meta-analysis evaluates optimal postoperative chemotherapy in early resected NSCLC
MDedge Hematology and Oncology